Scroll

cyclobenzaprine 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
	751	303-53-7

Description:

Molecule	Description
Molfile Inchi Smiles Synonyms: cyclobenzaprine proheptatrien proheptatriene cyclobenzaprine hydrochloride cyclobenzaprine HCl	structurally related to tricyclic antidepressants relieves skeletal muscle spasm of local origin without interfering with muscle function, it is ineffective in muscle spasm due to central nervous system disease Molecular weight: 275.40 Formula: C20H21N CLOGP: 4.96 LIPINSKI: 1 HAC: 1 HDO: 0 TPSA: 3.24 ALOGS: -4.60 ROTB: 3 Status: OFP Legend: OFP - off patent OFM - off market ONP - on patent

Molecule

Description

Molfile Inchi Smiles

Synonyms:

cyclobenzaprine
proheptatrien
proheptatriene
cyclobenzaprine hydrochloride
cyclobenzaprine HCl

structurally related to tricyclic antidepressants relieves skeletal muscle spasm of local origin without interfering with muscle function, it is ineffective in muscle spasm due to central nervous system disease

Molecular weight: 275.40
Formula: C20H21N
CLOGP: 4.96
LIPINSKI: 1
HAC: 1
HDO: 0
TPSA: 3.24
ALOGS: -4.60
ROTB: 3

Status: OFP

Legend:
OFP - off patent
OFM - off market
ONP - on patent

Drug dosage:

None

ADMET properties:

Show entries

Search:

Property	Value	Reference
BA (Bioavailability)	55 %	Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
S (Water solubility)	200 mg/mL	Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose)	1.37 µM/kg/day	Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BDDCS (Biopharmaceutical Drug Disposition Classification System)	1	Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine)	0.50 %	Benet LZ, Broccatelli F, Oprea TI
fu (Fraction unbound in plasma)	0.01 %	Kawashima H, Watanabe R, Esaki T, Kuroda M, Nagao C, Natsume-Kitatani Y, Ohashi R, Komura H, Mizuguchi K

Showing 1 to 6 of 6 entries

Previous1Next

Approvals:

Date	Agency	Company	Orphan
Aug. 26, 1977	FDA

FDA Adverse Event Reporting System (Female)

Show entries

Search:

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Completed suicide	1058.82	10.72	1166	89320	144507	63254029
Toxicity to various agents	768.92	10.72	1311	89175	245939	63152597
Sedation complication	617.52	10.72	329	90157	13493	63385043
Sedation	568.49	10.72	459	90027	38350	63360186
Creatinine renal clearance decreased	561.33	10.72	327	90159	15981	63382555
Orthostatic hypotension	492.54	10.72	410	90076	35750	63362786
Drug abuse	450.63	10.72	536	89950	71982	63326554
Blood calcium decreased	437.19	10.72	336	90150	26115	63372421
Cognitive disorder	424.07	10.72	458	90028	55357	63343179
Constipation	370.33	10.72	918	89568	224025	63174511

Showing 1 to 10 of 292 entries

Previous1 2 3 4 5…30Next

FDA Adverse Event Reporting System (Male)

Show entries

Search:

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Completed suicide	580.81	13.00	508	23969	97660	34834794
Drug abuse	264.86	13.00	336	24141	98760	34833694
Toxicity to various agents	239.54	13.00	469	24008	199893	34732561
Respiratory arrest	108.09	13.00	115	24362	27928	34904526
Cardio-respiratory arrest	63.97	13.00	128	24349	55145	34877309
Back pain	61.26	13.00	206	24271	121583	34810871
Milk-alkali syndrome	57.52	13.00	20	24457	585	34931869
Product dose omission issue	56.29	13.00	198	24279	119513	34812941
General physical health deterioration	49.91	13.00	14	24463	128255	34804199
Intentional product misuse	46.17	13.00	100	24377	45511	34886943

Showing 1 to 10 of 70 entries

Previous1 2 3 4 5 6 7Next

FDA Adverse Event Reporting System (Geriatric)

Show entries

Search:

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Completed suicide	1599.16	11.07	1690	91754	244077	79406867
Toxicity to various agents	944.44	11.07	1733	91711	419807	79231137
Sedation complication	671.28	11.07	340	93104	15329	79635615
Drug abuse	631.71	11.07	862	92582	161829	79489115
Creatinine renal clearance decreased	606.87	11.07	339	93105	18663	79632281
Sedation	556.95	11.07	472	92972	51423	79599521
Blood calcium decreased	467.10	11.07	348	93096	31471	79619473
Orthostatic hypotension	434.25	11.07	425	93019	55739	79595205
Cognitive disorder	430.23	11.07	468	92976	69458	79581486
Balance disorder	383.60	11.07	524	92920	98333	79552611

Showing 1 to 10 of 314 entries

Previous1 2 3 4 5…32Next

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Show entries

Search:

Source	Code	Description
ATC	M03BX08	MUSCULO-SKELETAL SYSTEM MUSCLE RELAXANTS MUSCLE RELAXANTS, CENTRALLY ACTING AGENTS Other centrally acting agents
CHEBI has role	CHEBI:35469	antidepressants
CHEBI has role	CHEBI:35473	tranquilizing drugs
CHEBI has role	CHEBI:51371	muscle relaxants
FDA EPC	N0000175737	Muscle Relaxant
FDA PE	N0000175730	Centrally-mediated Muscle Relaxation
MeSH PA	D000928	Antidepressive Agents
MeSH PA	D000929	Antidepressive Agents, Tricyclic
MeSH PA	D002491	Central Nervous System Agents
MeSH PA	D002492	Central Nervous System Depressants

Showing 1 to 10 of 15 entries

Previous1 2Next

Drug Use | Suggest Off label Use Form| |View source of the data|

Show entries

Search:

Disease	Relation	SNOMED_ID	DOID
Spasticity	indication	221360009
Fibromyalgia	off-label use	203082005	DOID:631
Sinus tachycardia	contraindication	11092001
Glaucoma	contraindication	23986001	DOID:1686
Hyperthyroidism	contraindication	34486009	DOID:7998
Conduction disorder of the heart	contraindication	44808001
Chronic heart failure	contraindication	48447003
Hepatic failure	contraindication	59927004
Open-angle glaucoma	contraindication	84494001	DOID:1067
Heart block	contraindication	233916004

Showing 1 to 10 of 12 entries

Previous1 2Next

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	8.66	Basic

Orange Book patent data (new drug applications)

Show entries

Search:

Formulation strength	Trade name	Applicant	Application number	Approval date	Type	Dose form	Route	Patent number	Patent expiration date	Patent use
15MG	AMRIX	TEVA PHARMS INTL	N021777	Feb. 1, 2007	RX	CAPSULE, EXTENDED RELEASE	ORAL	7544372	Nov. 14, 2023	RELIEF OF MUSCLE SPASM
15MG	AMRIX	TEVA PHARMS INTL	N021777	Feb. 1, 2007	RX	CAPSULE, EXTENDED RELEASE	ORAL	7829121	Nov. 14, 2023	RELIEF OF MUSCLE SPASM
15MG	AMRIX	TEVA PHARMS INTL	N021777	Feb. 1, 2007	RX	CAPSULE, EXTENDED RELEASE	ORAL	8877245	Nov. 14, 2023	RELIEF OF MUSCLE SPASM
15MG	AMRIX	TEVA PHARMS INTL	N021777	Feb. 1, 2007	RX	CAPSULE, EXTENDED RELEASE	ORAL	9375410	Nov. 14, 2023	RELIEF OF MUSCLE SPASM
15MG	AMRIX	TEVA PHARMS INTL	N021777	Feb. 1, 2007	RX	CAPSULE, EXTENDED RELEASE	ORAL	9399025	Nov. 14, 2023	RELIEF OF MUSCLE SPASM
30MG	AMRIX	TEVA PHARMS INTL	N021777	Feb. 1, 2007	RX	CAPSULE, EXTENDED RELEASE	ORAL	7544372	Nov. 14, 2023	RELIEF OF MUSCLE SPASM
30MG	AMRIX	TEVA PHARMS INTL	N021777	Feb. 1, 2007	RX	CAPSULE, EXTENDED RELEASE	ORAL	7829121	Nov. 14, 2023	RELIEF OF MUSCLE SPASM
30MG	AMRIX	TEVA PHARMS INTL	N021777	Feb. 1, 2007	RX	CAPSULE, EXTENDED RELEASE	ORAL	8877245	Nov. 14, 2023	RELIEF OF MUSCLE SPASM
30MG	AMRIX	TEVA PHARMS INTL	N021777	Feb. 1, 2007	RX	CAPSULE, EXTENDED RELEASE	ORAL	9375410	Nov. 14, 2023	RELIEF OF MUSCLE SPASM
30MG	AMRIX	TEVA PHARMS INTL	N021777	Feb. 1, 2007	RX	CAPSULE, EXTENDED RELEASE	ORAL	9399025	Nov. 14, 2023	RELIEF OF MUSCLE SPASM

Showing 1 to 10 of 10 entries

Previous1Next

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

Show entries

Search:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Bioact source	MoA source
5-hydroxytryptamine receptor 2A	GPCR	P28223	5HT2A_HUMAN	ANTAGONIST	Ki	7.54	WOMBAT-PK	CHEMBL
Multidrug resistance protein 1	Transporter	P08183	MDR1_HUMAN		IC50	4.73	WOMBAT-PK
Sodium-dependent serotonin transporter	Transporter	P31645	SC6A4_HUMAN		Ki	6.97	WOMBAT-PK
Sodium-dependent noradrenaline transporter	Transporter	P23975	SC6A2_HUMAN		Ki	7.44	WOMBAT-PK
5-hydroxytryptamine receptor 2C	GPCR	P28335	5HT2C_HUMAN	ANTAGONIST	Ki	7.24	WOMBAT-PK
5-hydroxytryptamine receptor 6	GPCR	P50406	5HT6R_HUMAN		Ki	6.84	WOMBAT-PK
5-hydroxytryptamine receptor 7	GPCR	P34969	5HT7R_HUMAN		Ki	6.82	WOMBAT-PK
Histamine H1 receptor	GPCR	P35367	HRH1_HUMAN		Ki	8.83	WOMBAT-PK
Muscarinic acetylcholine receptor M1	GPCR	P11229	ACM1_HUMAN		IC50	6.95	WOMBAT-PK
Muscarinic acetylcholine receptor M2	GPCR	P08172	ACM2_HUMAN		Ki	7.22	PDSP

Showing 1 to 10 of 15 entries

Previous1 2Next

External reference:

Show entries

Search:

ID	Source
001678	NDDF
004680	NDDF
217	MMSL
21949	RXNORM
2895	PUBCHEM_CID
373779004	SNOMEDCT_US
4017956	VANDF
4019699	VUID
4019699	VANDF
4517	MMSL

Showing 1 to 10 of 25 entries

Previous1 2 3Next

Pharmaceutical products:

Show entries

Search:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
Cyclobenzaprine Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	0093-1920	CAPSULE, EXTENDED RELEASE	15 mg	ORAL	NDA authorized generic	30 sections
Cyclobenzaprine Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	0093-1920	CAPSULE, EXTENDED RELEASE	15 mg	ORAL	NDA authorized generic	30 sections
Cyclobenzaprine Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	0093-1920	CAPSULE, EXTENDED RELEASE	15 mg	ORAL	NDA authorized generic	30 sections
Cyclobenzaprine Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	0093-1921	CAPSULE, EXTENDED RELEASE	30 mg	ORAL	NDA authorized generic	30 sections
Cyclobenzaprine Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	0093-1921	CAPSULE, EXTENDED RELEASE	30 mg	ORAL	NDA authorized generic	30 sections
Cyclobenzaprine Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	0093-1921	CAPSULE, EXTENDED RELEASE	30 mg	ORAL	NDA authorized generic	30 sections
Cyclobenzaprine Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	0093-3420	TABLET, FILM COATED	5 mg	ORAL	ANDA	20 sections
Cyclobenzaprine Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	0093-3421	TABLET, FILM COATED	7.50 mg	ORAL	ANDA	20 sections
Cyclobenzaprine Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	0093-3422	TABLET, FILM COATED	10 mg	ORAL	ANDA	20 sections
Cyclobenzaprine Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	0115-1436	CAPSULE, EXTENDED RELEASE	15 mg	ORAL	NDA AUTHORIZED GENERIC	28 sections

Showing 1 to 10 of 30 entries

Previous1 2 3Next